Biomarkers indicative of prostate cancer and treatment thereof
AssigneeUniversity of Miami
InventorsKerry L. Burnstein, Fiorella Magani
Life of this patent
Estimating the term…
Abstract
Described herein are materials and methods for the treatment of prostate cancer.
Claims14
A method of decreasing proliferation of prostate cancer cells comprising contacting the cells with doxorubicin (DOX) and N9-isopropylolomoucine (N-9) in an amount effective to decrease proliferation of the cancer cells, wherein the prostate cancer is castrate-resistant prostate cancer (CRPC).
A method of treating prostate cancer in a subject in need thereof comprising administering to the subject doxorubicin (DOX) and N9-isopropylolomoucine (N-9) a mitotic cyclin dependent kinase inhibitor in amounts effective to treat prostate cancer in the subject, wherein the prostate cancer is castrate-resistant prostate cancer (CRPC).
A method of treating prostate cancer in a subject in need thereof comprising
- (a) identifying elevated levels of kinesin family-member 20A (KIF20A), kinesin family-member 23 (KIF23), topoisomerase DNA II alpha (TOP2A), cyclin B1 (CCNB1) cyclin B2 (CCNB2), mitotic checkpoint serine/threonine kinase (BUB1) and mitotic checkpoint serine/threonine kinase B (BUB1b) in a tumor sample from the subject relative to a reference standard;
- and
- (b) administering doxorubicin (DOX) and a mitotic cyclin dependent kinase inhibitor in amounts effective to treat prostate cancer in the subject.
Dependencies are inferred from the claim text.